I have lost any faith in this company as a long time stock holder. I would be ashamed to be on their board. I have written the public relations office with questions and comments on many occasions with not one answer. I was partially motivated to invest in this stock because they were working to accomplish something good for humanity. It certainly has been. a total loser as an investment and it just keeps getting worse. It is so low that it isn't even worth selling except for a loss. Shame on management!!!
Two things would boost the share price tremendously: (like over $4)
1. Announcement of INSPIRE resuming recruitment 2. Replacement of Mark Perrin with a more skillful CEO
Bonus: An authoritative restatement of the already known fact that patient deaths have nothing to do with the NSS and procedure. That recruitment of patients have tended toward the more risky due to missed opportunities by study sites to recruit less risky patients.
The MP report, August 17, 2017.
The CEO has failed this company and he has failed its investors both retail and institutional. How many months has he been like a deer in the headlights and has made poor decision after poor decision. He's been a horrific steward of the company funds. He has presided over 90% evaporation of the market cap, during which time the company has ironically made strides forward, albeit in low gear. This failed CEO has not had the wherewithal to convey to Wall Street the intrinsic value of the future product. Furthermore, within the strict constraints of how to deal with the PI's and their staffs at the study sites, he has failed to keep up enthusiasm. This failure has lead to excessive complacency and missed opportunities to capture a high percentage of patients into INSPIRE. So much so, that they have recruited a disporoportionate amount of patients with huge risk of death. That could have been totally avoidable had more sites stepped up to the plate and not let so many patients fall through the cracks. About all this has served to do is to put to bed the ridiculous short theory of alleged selection bias, which is the most absurd notion one can imagine. But what good is disproving a ridiculous theory when the study could have been completed and attained approval had the recruitment not missed so many qualified patients.
I propose that while the share holders continue to get their #$%$ handed to them, management donate their unearned salaries to children's charities...this at least would make me feel better. Share the pain.
Naked Short Report, Nasdaq and NYSE Naked Short Positions, Short Selling Interest
Naked Short Report - track short selling interest on NASDAQ and NYSE STOCKS, check daily short interest, naked short data and short squeeze stock perfomance
Although the share price is pathetically low, and up until recently unjustifiably so, the latest "strategic" moves a/k/a fumbles by Perrin have delayed the long play, so actually it is anyones guess what happens next. The warrant conversion was a protective measure or stopgap to guard against that being a larger liability (so that is supporting the SP after its drop), but the unknown delay time is unfortunate. Only 4 more patients to enroll and go 6 months, but this holding pattern really throws it up in the air. A couple things to note: Although there is no evidence linking patient deaths with INSPIRE (good), we have an indeterminate delay (bad), though the fact that there have been fatalities ought to put to bed the ridiculous short speculation of "selective bias" which was always an absurd thesis, and even more repudiated by the desperateness of PI's flirting with using such fragile patients. Obviously no cherry-picking going on! They need to get INSPIRE going again as quickly as possible. I understand the sites need to sign off on any changes, but why can't the study resume at the individual pace of sites coming back online. Probably the ones who were not Hall of Shame contenders (active sites instead of on paper only) will sign off more quickly anyway, so a staggered restart should be fine. I find it hard to believe that it is all or nothing like a jury needing to be unanimous or there's a retrial. Anyway time is of the essence. Long thesis on temporary hold thanks to Perrin's mismanagement.
I have a feeling Perrin is going to have a very hard time finding some savvy investor to take his next offering. Thats going to lead to what Perrin does best and thats BK.
I put on the computer hoping to see a PR from this company saying The BOD's have elected to terminated MP's contract with Invivo and Domagoj Coric, M.D is now CEO
So, what's up with this company now?? Good time to get in?
exchange of warrants added insult to injury. great timing. right after the clinical hold. for a company that wants to help people with spinal injuries, it sure knows how to cripple its investors. very disappointed as an investor. it happens ... always stay diversified and don't put too many eggs in one basket ....glta
Dow futures up 124 points. That should translate into a 2 cent gain for us. The loser CEO and BOD's. A bunch of loser's
I cannot believe this situation. Friends and family invested based on the science. The science has passed the test unless some of the reported results have been falsified. This would be criminal behavior and unbelievable. Why else would insiders not buy shares? What do they know? My potential loss as a long term investor is huge. I cannot explain the CEO lack of polish and misdirected judgment but the consequences are painful for way too many early investors. As a long ago spinal injury patient I value the science in an emotional and economic way especially with regard to newly paralyzed young people. NVIV twiddles as their window of recovery closes and shareholders struggle to understand why our company has shifted INSPIRE into neutral.
Buy low; sell high! This is low.
I bought at the beginning of the month, but had to break a rule and buy today, because the price was such a gift.
Those complaining about the CEO do not understand that he doesn't get to "sell" the device to patients, hospitals, or PIs. I wrote a post awhile back, explaining why patients/family may not want to try a device with no proven efficacy that involves major surgery. I will repost it for those who are interested.
Another consideration: Some sites may not be signing up because they are anxious to perform an experimental surgery with no proven efficacy. They may, however, see the benefit in being up and running when the FDA gives the nod. Even after the FDA gives the nod to go ahead, trauma centers wishing to implant the device will still need to have IRB approval. Better to already have it and be a "part" of the initial study, than completely sitting on the sidelines.
We need to enroll four more patients - OTOH, maybe the FDA could change back to the original 20 not "20 evaluable" patients. Then we would only need one more patient. NVIV is currently sitting on a 35% conversion rate with 4 patients still in evaluation. Adding one more patient would give us five patients in evaluation, of which one might convert just by chance (15% * 5 = .75). Rounded up, that equals one patient.
There is so much good happening with this stock it is ridiculous. The price is not relevant. The price is driven by people who do not understand the science or the progress that has been made to date. Or, it is driven by retail investors who are traders and need to have a small profit rather than waiting for a 10/20 bagger.
Nobody owns enough NVIV
Conversion statistics: OPC = 25% NVIV @ 35%
Safety profile: 100% safe.
Maybe the FDA and our company will agree that we only need to prepare a modified patient disclosure form for potential new enrollments to provide new and complete information surrounding the 3 patient deaths. With full disclosure the trial would be able to resume without getting participant approvals except for the increment of new patients at the time of candidacy. Even our company could negotiate and implement this approach straight away..
1.20 was the bottom and watch what happens when NVIV is back on track with the new FDA protocol...patience
Regarding the most recent trial halt per the 10Q, FDA has responded with recommendations and revisions to the protocol are anticipated. These changes will not only need to be approved by the FDA before reopening the trial but also requires reapproval from each enrollment site.
This unfortunately verifies delays will stretch MONTHS. Last trial halt was roughly 3 to 4 months as Invivo also needed approvals from each site. Company will continue to waste another 6+ million dollars at the current burn rate...
Nice work Perrin
I stuck around for the science, but got taken for a ride by management...most useless CEO of all time. Never bought a single share and failed every step of the way. Shorts won this one.
$37-$38M Market Cap for a company that has over $20M in cash, no debt, significant intellectual property in the form of patents on products and processes in an area that has little to no competition with significant results that can Globally change the medical world with regards to SCI... this is beyond comprehension logically. Its seriously unfortunate that money rules in good vs evil... its a shame big money cannot back good and improve the future survival of human beings rather than oppose it for a buck.
No news anytime soon, he's probably in Martha's Vineyard enjoying his ill gotten gains...
Envy vo, your as much a culprit on the positive side as Creed is on the negative side. The one thing that separates you two on a daily basis is that Creed shows up daily. You and your seemingly endless "NO ONE OWNS ENOUGH SHARES" are endless. We hear from you or should I say sorry #$%$ maybe once a month and this has been going on since the old Yahoo message board. oh and you were touting no one owns enough at the price of 12 dollars. Face it the CEO is a failure and the BODs are a bigger failure stating with Ann Merrifield and the slim bag guy from the Miami project